At Auriga Research, we are at the forefront of ensuring the safety and efficacy of pharmaceutical products through our comprehensive pharmacovigilance (PV) services. Our PV framework is designed to comply with stringent global regulatory standards, leveraging advanced methodologies and state-of-the-art technologies to monitor and evaluate the safety profiles of medicinal products. This systematic approach ensures we maintain the highest levels of compliance and safety, both domestically and internationally.
Pharmacovigilance (PV) is a scientific discipline that involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. PV is integral to maintaining the benefit-risk balance of medicinal products throughout their lifecycle. It encompasses various activities aimed at ensuring that the benefits of a drug outweigh its risks, thereby safeguarding public health.
Compliance with national and international regulatory requirements, such as those established by the FDA, EMA, DCGI, and PVPI, is critical. Pharmacovigilance activities are essential to meet these regulatory obligations, which are pivotal for market authorization and continued marketing of pharmaceutical products.
Adverse Event Reporting
This involves the systematic collection, analysis, and submission of individual case safety reports (ICSRs) for adverse events to regulatory authorities. Timely reporting is crucial to mitigate risks associated with medicinal products.
Periodic Safety Update Reports (PSURs)
Regular updates to regulatory authorities on the safety profile of a drug, providing a comprehensive evaluation of the benefit-risk balance over defined periods.
Risk Management Plans (RMPs)
Detailed strategies to identify, assess, and mitigate risks associated with medicinal products. RMPs outline the measures to minimize risks and monitor their effectiveness.
Signal Detection and Evaluation
Continuous monitoring for new safety signals and assessing their potential impact. This involves advanced statistical methods and data mining techniques to detect emerging safety issues.
Literature Surveillance
Ongoing review of scientific literature to identify any new information related to drug safety, ensuring all emerging safety data is captured and analyzed promptly
Benefit-Risk Assessment
Regular evaluation of the benefits and risks of a drug to ensure a positive benefit-risk balance, guiding informed decision-making.
At Auriga Research, we employ a structured and efficient approach to manage pharmacovigilance activities:
Our pharmacovigilance services are supported by robust software features that enhance efficiency and accuracy:
Automated Case Processing
Streamlined workflows for faster and more accurate case processing.
Real-Time
Monitoring
Immediate detection and reporting of adverse events, ensuring timely action.
Data
Integration
Seamless integration with other systems for comprehensive safety data management.
Advanced
Analytics
In-depth analysis and visualization tools for better decision-making.
Regulatory
Compliance
Built-in compliance with regulatory reporting requirements, ensuring global standards are met.
In India, pharmacovigilance activities must comply with guidelines set by the Central Drugs Standard Control Organization (CDSCO) and the Drug Controller General of India (DCGI). Key requirements include:
Timely submission of ICSRs to the national pharmacovigilance database, ensuring prompt action on safety issues.
Regular submission of periodic safety update reports and risk management plans to demonstrate ongoing safety monitoring.
Regular audits to ensure adherence to regulatory guidelines and standards, maintaining high levels of compliance and safety.
For global operations, compliance with international regulatory authorities such as the FDA (USA), EMA (Europe), and WHO is essential. Key international requirements include:
Harmonized reporting of adverse events to multiple regulatory authorities, ensuring consistent and comprehensive safety monitoring.
Submission of global safety reports and risk management plans to international regulators, demonstrating proactive safety management.
Regular inspections by international regulatory bodies to ensure compliance with global standards, maintaining the credibility and reliability of PV activities.